Submitted to: Campylobacter Helicobacter and Related Organisms International Workshop
Publication Type: Abstract only
Publication Acceptance Date: 8/6/2007
Publication Date: 9/3/2007
Citation: Svetoch, E.A., Eruslanov, B.V., Perelygin, V.V., Mitsevich, E.V., Mitsevich, I.P., Borzenkov, V.N., Levchuk, V.P., Svetoch, O.E., Seal, B.S., Stern, N.J. 2007. Bacteriocin from Enterococcus faecium NRRL B-30746 (E 50-52) kills Campylobacter jejuni in broilers. Campylobacter Helicobacter and Related Organisms International Workshop. P 117, #P361. Interpretive Summary:
Technical Abstract: The effectiveness of antibiotics in resolving bacterial infections has been compromised by the increased prevalence and magnitude of antibiotic resistance. In our efforts to identify new effective antimicrobials, bacteria isolated from poultry intestinal content were screened for bacteriocin synthesis against Campylobacter jejuni NCTC 11168. From this iterative screening process the bacteriocin producing bacterium Enterococcus faecium (NRRL B-30746) was selected for detailed study. The isolate was grown in broth, the cell-free supernatant was precipitated, the precipitate dialyzed and, multiple chromatographic steps were used to purify the antimicrobial peptide to single band homogeneity. Based on genetic and biochemical traits obtained the antimicrobial peptide was identified as Class IIa bacteriocin and named E50-52. The peptide has a molecular weight of 3,339.7 + 0.3 Da and pI of 8.5. The MIC of the peptide for 96 isolates of C. jejuni ranged from 0.025 to 6.4 µg/ml. In therapeutic broiler chicken challenge trials, oral treatment with E50-52 reduced both Campylobacter jejuni and Salmonella enteritidis by >100,000-fold in the ceca and, systemic S. enteritidis was reduced in the liver and spleen. The wide range of antimicrobial activity against pathogens exhibited by bacteriocin E 50-52 traverses the Gram positive and Gram negative barriers. E50-52 may serve as a promising antibiotic alternative.